Patient P-03031
Therapy response
Declining
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
47%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S16
- Day 102 CR-01 recommended — Clinician Review CR-01
- Day 103 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 103 Patient accepted — Started CR-01 in the companion
- Day 108 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 103.
Primary contributors, last 14 days
- Toxicity+9
- Treatment adherence-8
- Nutritional resilience-4
- Inflammatory activity+3
- GI instability+2
What helped?
- Clinician Review CR-01Day 102Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
52%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 50
- WearableHRV 22 ms, trending down
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.6 · butyrate capacity 46/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 21 ms
- Sleep
- 6.4 h
- Steps
- 4,955
- Resting HR
- 67 bpm
Daily log: GI score 48, nutritional resilience 45, adherence 74.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03225 | 44% | S19 | GI-04 | improved | 50 |
| P-03382 | 44% | S01 | GI-04 | improved | 56 |
| P-03379 | 41% | S12 | GI-04 | improved | 51 |
| P-03166 | 37% | S20 | CR-01 | improved | 62 |
| P-03191 | 37% | S19 | GI-04 | improved | 51 |
| P-03099 | 36% | S17 | CR-01 | improved | 55 |
| P-03226 | 36% | S05 | GI-04 | improved | 43 |
| P-03159 | 35% | S14 | GI-04 | improved | 37 |
| P-03365 | 35% | S14 | NP-02 | improved | 46 |
| P-03201 | 34% | S15 | GI-04 | improved | 68 |
| P-03465 | 34% | S17 | CR-01 | improved | 65 |
| P-03145 | 33% | S14 | GI-04 | improved | 51 |